Drugs / iNKT cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03175679 | Apr 2017 → Dec 2018 | hepatocellular carcinoma | Beijing YouAn Hospital | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03551795 | Jan 2018 → Dec 2021 | cancer | Xiaoyan Zhang | Completed | No outcome recorded |
| Phase 1/2 | NCT03093688 | Mar 2017 → Dec 2030 expected | gastric cancer, hepatocellular carcinoma, malignant pancreatic neoplasm, non-small cell lung carcinoma +2 | Shanghai Public Health Clinical Center | Recruiting | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05962450 | Oct 2023 → Aug 2025 | hepatocellular carcinoma | Beijing YouAn Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04011033 | Mar 2018 → Mar 2020 | hepatocellular carcinoma | Beijing YouAn Hospital | Completed | Met primary |
News releases announcing trial results or a regulatory action · 28
| Date | Issuer | Release |
|---|---|---|
| 2026-10-02 | MiNK Therapeutics | Results MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 minktherapeutics.com ↗
Native and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment |
| 2026-05-20 | MiNK Therapeutics | Results MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications minktherapeutics.com ↗
The new findings also support MiNK’s broader platform thesis that iNKT cells may respond dynamically to the immune environment they encounter, with potential relevance across oncology, severe lung injury, persistent infection and immune dysfunction. |
| 2026-05-12 | MiNK Therapeutics | Results MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 minktherapeutics.com ↗
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 |
| 2026-02-03 | MiNK Therapeutics | Results MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia minktherapeutics.com ↗
The Keystone data show that iNKT cells—key regulators of immune homeostasis—are significantly depleted in lung-associated lymphoid tissue in patients with advanced IPF compared with donor controls. |
| 2025-09-25 | MiNK Therapeutics | Results MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA minktherapeutics.com ↗
In her remarks, Dr. Buell will share first-in-human data from MiNK’s iNKT platform demonstrating durable disease reversal and steroid-free remission in severe immune collapse. |
| 2025-07-11 | MiNK Therapeutics | Results MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer minktherapeutics.com ↗
The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. |
| 2025-05-14 | BrightPath Biotherapeutics | Results BCMA CAR-ipsNKT細胞（BP2202）の製造工程開発の進捗に関するデータを米国遺伝子治療学会議ASGCT 2025で発表 brightpathbio.com ↗ |
| 2025-04-30 | BrightPath Biotherapeutics | Results iPS細胞由来CAR-NKT細胞の非臨床試験データをAACR 2025で発表 brightpathbio.com ↗ |
| 2025-02-24 | MiNK Therapeutics | Results MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting minktherapeutics.com ↗ |
| 2024-11-21 | GRI Bio Operations, Inc. | Results GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) gribio.com ↗
Data demonstrate that NKT cells are activated in airways in IPF patients and inhibition of iNKT cell activity with GRI-0621 ameliorates pulmonary fibrosis in a preclinical model |
| 2024-11-07 | MiNK Therapeutics | Results MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 minktherapeutics.com ↗
The presentations showcased new data from MiNK’s iNKT cell therapy programs, agenT-797 and PRAME-TCR. |
| 2024-10-16 | GRI Bio Operations, Inc. | Results GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) gribio.com ↗
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis |
| 2024-07-02 | GRI Bio Operations, Inc. | Results GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine gribio.com ↗
Inhibition of iNKT activity led to a decrease in fibrosis score and total lung inflammation. |
| 2024-05-22 | MiNK Therapeutics | Results MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting minktherapeutics.com ↗ |
| 2024-05-20 | GRI Bio Operations, Inc. | Results GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) gribio.com ↗
Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung inflammation |
| 2024-03-06 | MiNK Therapeutics | Results MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 minktherapeutics.com ↗
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model |
| 2024-02-06 | MiNK Therapeutics | Results MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications minktherapeutics.com ↗
These findings show that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile. |
| 2024-01-30 | MiNK Therapeutics | Results MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene minktherapeutics.com ↗
one infusion of agenT-797 in gastric cancer refractory to anti-PD1 led to a durable confirmed partial response |
| 2023-11-09 | MiNK Therapeutics | Results MiNK Therapeutics Reports Third Quarter 2023 Results minktherapeutics.com ↗
MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning. |
| 2023-11-03 | MiNK Therapeutics | Results MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023 minktherapeutics.com ↗
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023 |
| 2023-10-05 | GRI Bio Operations, Inc. | Results GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions gribio.com ↗
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting |
| 2023-05-22 | MiNK Therapeutics | Results MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference minktherapeutics.com ↗
75% survival in patients with severe respiratory distress treated with agenT-797 |
| 2023-05-18 | MiNK Therapeutics | Results MiNK's Novel FAP-CAR-iNKT Presented at ASGCT minktherapeutics.com ↗
Robust efficacy in non-small cell lung cancer (NSCLC) models, resulting in substantial tumor elimination in the lungs and improved survival compared to T cells alone. |
| 2023-04-18 | MiNK Therapeutics | Results MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting minktherapeutics.com ↗
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting |
| 2022-11-10 | MiNK Therapeutics | Results MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline minktherapeutics.com ↗
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilization |
| 2022-03-31 | Portage Biotech | Results Portage Biotech Provides Update on Clinical-Stage and Development Programs portagebiotech.com ↗
“We are pleased to report that as expected, Portage’s invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT -3, were well tolerated in initial clinical studies ,” said Dr. Ian Walters, chief executive officer of Portage. |
| 2021-11-12 | MiNK Therapeutics | Results MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797 minktherapeutics.com ↗
iNKTs demonstrated potent preclinical tumor killing and cytotoxicity in solid and liquid cancers with a reduction in tumor size in the iNKT treated models. |
| 2014-02-28 | Regimmune Corporation | Results American Journal of Transplantation Reports REGiMMUNE’s Preclinical Results of its Method for Long-term Tolerance in Organ Transplantation regimmune.com ↗
Mechanistic studies of this combination treatment revealed a synergistic expansion of tolerogenic dendritic cells (plasmacytoid dendritic cells) that results in the downstream increase of regulatory T cells. |
All press releases naming this drug 30 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNKT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03093688 ↗ |
| Known as | Invariant Natural killer T | “Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes” NCT03093688 ↗ |
| Action | Deplete | “Human iNKT cells can directly lysis tumor cells by a perforin-dependent mechanism” NCT03093688 ↗ |
| Modality | Cell therapy | “immunotherapy strategy of infusion of iNKT cells” NCT03551795 ↗ |
| Route | Intravenous | “through intravenous infusion” NCT03175679 ↗ |